241 related articles for article (PubMed ID: 38286636)
1. Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.
Beers JL; Zhou Z; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):508-515. PubMed ID: 38286636
[TBL] [Abstract][Full Text] [Related]
2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
3. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
Anderson LL; Absalom NL; Abelev SV; Low IK; Doohan PT; Martin LJ; Chebib M; McGregor IS; Arnold JC
Epilepsia; 2019 Nov; 60(11):2224-2234. PubMed ID: 31625159
[TBL] [Abstract][Full Text] [Related]
4. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
Morrison G; Crockett J; Blakey G; Sommerville K
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1009-1031. PubMed ID: 30791225
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.
Beers JL; Fu D; Jackson KD
Drug Metab Dispos; 2021 Oct; 49(10):882-891. PubMed ID: 34330718
[TBL] [Abstract][Full Text] [Related]
7. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
11. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids.
Li J; Zagorski JW; Kaminski NE
Toxicology; 2023 Apr; 488():153469. PubMed ID: 36863504
[TBL] [Abstract][Full Text] [Related]
13. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
14. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial.
Watkins PB; Church RJ; Li J; Knappertz V
Clin Pharmacol Ther; 2021 May; 109(5):1224-1231. PubMed ID: 33022751
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration.
Ewing LE; McGill MR; Yee EU; Quick CM; Skinner CM; Kennon-McGill S; Clemens M; Vazquez JH; McCullough SS; Williams DK; Kutanzi KR; Walker LA; ElSohly MA; James LP; Gurley BJ; Koturbash I
Molecules; 2019 Jun; 24(12):. PubMed ID: 31212965
[TBL] [Abstract][Full Text] [Related]
18. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
19. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
[TBL] [Abstract][Full Text] [Related]
20. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
